English  |  正體中文  |  简体中文  |  Items with full text/Total items : 54371/62179 (87%)
Visitors : 8720281      Online Users : 104
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTHU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    National Tsing Hua University Institutional Repository > 生命科學院  > 分子與細胞生物研究所 > 博碩士論文  >  人類組蛋白去甲基酵素KDM4B之天然抑制劑開發


    Please use this identifier to cite or link to this item: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/86875


    Title: 人類組蛋白去甲基酵素KDM4B之天然抑制劑開發
    Authors: 吳健銘
    Wu, Chien Ming
    Description: GH02102080519
    碩士
    分子與細胞生物研究所
    Date: 2015
    Keywords: 表關遺傳學 組蛋白去甲基酵素 組蛋白去甲基酵素抑制劑 天然抑制劑
    Epigenetics KDM4B JMJD2B Demethylase inhibitor Natural products
    Abstract: 關遺傳學是在不改變DNA序列下,進一步調控基因的表現。包含DNA的甲基化和組蛋白後轉錄修飾。其中一種組蛋白修飾為組蛋白甲基和去甲基化,被甲基轉移酵素和組蛋白去甲基酵素調控。在許多種癌症中發現,甲基轉移酵素和組蛋白去甲基酵素的作用已經失調。主要的組蛋白去甲基酵素都包含一段Jumonji-C domain,同時利用2-oxoglutarate和二價鐵離子進行去甲基的功能。KDM4B是其中一種的去甲基酵素,作用於H3K9me3/me2以及H3K36me3/me2,另一方面KDM4B在許多種癌症中的表現量都偏高,例如:胃癌,腎臟癌,直腸癌,乳癌和前列腺癌。其中在前列腺癌上,KDM4B和AR receptor共同作用促進細胞增長因此我們假設KDM4B可以作為一個治療癌症的目標蛋白。在這篇論文中,我們希望可以探討可以抑制KDM4B活性的天然抑制劑。在蛋白質和分子結構的研究下,我們發現一個天然物M2可以抑制KDM4B(IC50:12.2 μM,Ki:2.72μM),同時會和反應物有一個競爭的關係。另一方面,M2也可以抑制其他KDM4的去甲基酵素。在細胞的實驗中,M2會在CWR22Rv1,LNCaP,LNCaP C4-2B和PC-3的細胞上,產生毒性,同時也發現KDM4B的主要反應物H3K9me3在細胞的表現量也提升。最後總結我們的實驗,認為M2可以被視為可以發展為抗癌藥物的方向,未來我們將開發M2的衍生物,進一步提升抑制性和靈敏度。
    Epigenetics is the study of transcriptional and physiological trait variations that do not involve changes in the DNA sequence. DNA methylation and post-translational modification in the histone tail are major mechanisms that produce such changes. One of histone modifications, methylation/demethylation, is controlled by histone methyltransferase and histone demethylase has been recently studied. Dysregulation of histone methylation/demethylation is found to be associated with various types of cancer. The major type of lysine demethylase (KDM) consists of Jumonji-C (JmjC) domain (KDM2?KDM8) and requires 2-oxoglutarate and Fe(II) as cofactors to remove the methyl moiety from the histone tail. Of those, KDM4B, a member of the KDM4 family can specifically remove the methyl group from H3K9me3/me2 and H3K36me3/me2. KDM4B are overexpressed in many types of cancer including gastric cancer, renal cancer, colon cancer, breast cancer and prostate cancer. In prostate cancer, KDM4B is a co-activator of androgen receptor (AR) to stimulate cell growth. Given the important role of AR in prostate carcinogenesis, we propose KDM4B as a useful target protein. In this study, we aim to discover natural compounds that inhibit KDM4B based on a structure-guided approach. We have successfully identified a compound M2 with IC50 = 12.2 ± 1.6 μM, Ki= 2.72 μM. M2 exhibits a competitive inhibition mode toward KDM4B. M2 also shows inhibition against other members of the KDM4 family but not against PHF8. In cell-based experiment, M2 had cytoxicity in AR-dependent (LNCaP) as well as AR-independent prostate cancer cells (CWR22Rv1, LNCaP C4-2B and PC-3). Addition of M2 in LNCaP and CWR22Rv1 cells led to the increase of H3K9m3 signal. Together, M2 is a specific KDM4 inhibitor and shows anti-prostate cancer effect. Future work is to derive M2-based compounds with higher specificity and potency.
    URI: http://nthur.lib.nthu.edu.tw/dspace/handle/987654321/86875
    Source: http://thesis.nthu.edu.tw/cgi-bin/gs/hugsweb.cgi?o=dnthucdr&i=sGH02102080519.id
    Appears in Collections:[分子與細胞生物研究所] 博碩士論文

    Files in This Item:

    File SizeFormat
    GH02102080519.pdf196KbAdobe PDF219View/Open


    在NTHUR中所有的資料項目都受到原著作權保護,僅提供學術研究及教育使用,敬請尊重著作權人之權益。若須利用於商業或營利,請先取得著作權人授權。
    若發現本網站收錄之內容有侵害著作權人權益之情事,請權利人通知本網站管理者(smluo@lib.nthu.edu.tw),管理者將立即採取移除該內容等補救措施。

    SFX Query

    與系統管理員聯絡

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback